MARKET

VSTM

VSTM

Verastem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.680
-0.010
-0.37%
After Hours: 2.660 -0.02 -0.75% 18:44 04/16 EDT
OPEN
2.720
PREV CLOSE
2.690
HIGH
2.720
LOW
2.630
VOLUME
1.19M
TURNOVER
--
52 WEEK HIGH
4.670
52 WEEK LOW
1.080
MARKET CAP
460.06M
P/E (TTM)
-5.0585
1D
5D
1M
3M
1Y
5Y
ANPC, KLDO, CGEN and CLPS among after-hours movers
Gainers: [[ANPC]] +32.0%. [[KLDO]] +3.4%. [[EBON]] +3.3%. [[VYGR]] +3.1%. [[RAIL]] +2.6%.Losers: [[CGEN]] -2.7%. [[RXRX]] -2.6%. [[CLPS]] -2.3%. [[LIZI]] -2.1%. [[VSTM]] -1.9%.
Seekingalpha · 2d ago
Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Professional Survey Market Insights, Overview, Analysis and Forecast 2021-2026
Apr 16, 2021 (Heraldkeepers) -- Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation. Product values and regional...
Heraldkeepers · 2d ago
Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market By Type, By Application, By Segmentation, By Region, and By Country
Heraldkeepers · 2d ago
Innovative Diagnostic Methods Remains Vital in the Fight Against Cancer
, /PRNewswire/ -- The cancer treatment market is one of the biggest segments of the biotechnology industry. According to the National Cancer Institute, roughly 1.8 million people were diagnosed with cancer in in 2020. Overall, lung and bronchus cancer is...
PR Newswire - PRF · 04/09 13:00
Focal Adhesion Kinase Market 2021 Analysis by Key Players, End-User, Type, Application, Regions and Forecast to 2027
Apr 09, 2021 (Market Insight Reports) -- The latest report as Focal Adhesion Kinase Market acknowledges Size, Application Segment, Type, Regional Outlook,...
Market Insight Reports · 04/09 07:19
Focal Adhesion Kinase Market Overview, SWOT Analysis, Applications,Trends and Forecast 2020-2027 by Ameco Research
pune, India, Tue, 30 Mar 2021 02:18:15 / Comserve Inc. / -- The "Focal Adhesion Kinase Market - Market Analysis, Trends, and Forecasts" report has been added...
Comserve · 03/31 13:09
Global Focal Adhesion Kinase Market Insights, Overview, Analysis and Forecast 2015-2026
Heraldkeepers · 03/30 17:06
How Much Of Verastem, Inc. (NASDAQ:VSTM) Do Institutions Own?
A look at the shareholders of Verastem, Inc. ( NASDAQ:VSTM ) can tell us which group is most powerful. Institutions...
Simply Wall St. · 03/30 14:51
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VSTM. Analyze the recent business situations of Verastem through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VSTM stock price target is 4.500 with a high estimate of 6.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 199
Institutional Holdings: 87.52M
% Owned: 50.98%
Shares Outstanding: 171.67M
TypeInstitutionsShares
Increased
42
7.15M
New
27
23.80M
Decreased
28
707.83K
Sold Out
18
9.99M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
President/Chief Operating Officer
Daniel Paterson
Chief Executive Officer/Director
Brian Stuglik
Chief Financial Officer
Robert Gagnon
Lead Director/Independent Director
Michael Kauffman
Independent Director
Timothy Barberich
Independent Director
Gina Consylman
Independent Director
Alison Lawton
Independent Director
Eric Rowinsky
Independent Director
Bruce Wendel
No Data
About VSTM
Verastem, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s marketed and developing products include defactinib and VS-6766. Defactinib is an oral small molecule inhibitor of FAK and PYK2 that is being evaluated as a potential combination therapy for various solid tumors. It is engaged in running clinical trials in cancers where there are limited treatment options, including leukemia, lymphoma, lung cancer, mesothelioma, ovarian cancer, head and neck cancer, colorectal cancer and pancreatic cancer. VS-6766 is an inhibitor of the RAF/MEK signaling pathway. VS-6766 blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK.

Webull offers kinds of Verastem Inc stock information, including NASDAQ:VSTM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VSTM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VSTM stock methods without spending real money on the virtual paper trading platform.